Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–164 of 164 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Human Papillomavirus (HPV) Vaccines Clear all

Conditions: Human Papillomavirus Vaccines, Adolescent Health Services
Interventions: Project ECHO, Announcement Approach Training, Recall notices; Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Human Papillomavirus Infection
Interventions: Compliance, Message sidedness; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 11 Years to 15 Years
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Anal Cancer, Nonneoplastic Condition, Penile Cancer, Precancerous Condition
Interventions: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, laboratory biomarker analysis; Biological · Other
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 13 Years to 26 Years · Male only
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 18
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 10 more

Conditions: Human Papillomavirus Infection
Interventions: Assessment Feedback Incentives and eXchange, Physician-to-physician engagement, Active Intervention Control; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: Not listed
Enrollment: 264 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 3
States / cities: Phoenix, Arizona • Albany, New York • Madison, Wisconsin

Conditions: Human Papillomavirus Vaccination
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 13 Years to 17 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Cervical Cancer, Hpv, Warts
Interventions: Quadrivalent HPV for types 6, 11, 16 and 18; Biological
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 9 Years to 17 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Conditions: HIV Infections
Interventions: Quadrivalent HPV Vaccine, Placebo Vaccine for Male Participants Only, Placebo Vaccine for Female Participants Only; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 27 Years and older
Enrollment: 575 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 22
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 14 more

Conditions: Human Papilloma Virus Infection Type 11, Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Human Papilloma Virus Infection Type 6, Cervical Cancer
Interventions: THEO; Other
Lead sponsor: Regenstrief Institute, Inc.; Other
Eligibility: 11 Years to 17 Years
Enrollment: 1,306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Indianapolis, Indiana

Conditions: Chronic Kidney Disease
Interventions: Gardasil® Vaccine (FDA-approved vaccination regimen); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 9 Years to 21 Years · Female only
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 2
States / cities: Atlanta, Georgia • Baltimore, Maryland

Conditions: Human Papillomavirus (HPV)
Interventions: Survey; Other
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 9 Years to 26 Years · Male only
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 7
States / cities: Chicago, Illinois • Evanston, Illinois

Conditions: Vaccine Preventable Diseases, Meningococcal Disease, Human Papillomavirus, Pertussis, Influenza
Interventions: Point-of-Care Prompt; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 11 Years to 18 Years
Enrollment: 7,040 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 22
States / cities: Little Rock, Arkansas • Wilmington, Delaware • Gainesville, Florida + 12 more

Conditions: HIV Positive, Anal Condylomata, Anal Warts, HIV Infections
Interventions: Saline, Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Patient Compliance
Interventions: HPV Vaccine Electronic Reminders; Behavioral
Lead sponsor: East Carolina University; Other
Eligibility: 9 Years to 17 Years
Enrollment: 522 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Greenville, North Carolina • Snow Hill, North Carolina

Conditions: Health Knowledge, Attitudes, Practice, Vaccine-Preventable Diseases, Intention, Adherence, Patient
Interventions: Culturally Tailored Multimedia Psychoeducational HPV Intervention, General HPV Multimedia Psychoeducational Control Group; Behavioral
Lead sponsor: University of Texas, El Paso; Other
Eligibility: 18 Years to 45 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Immunization, HPV Infection, Human Papillomavirus
Interventions: 9-valent HPV vaccine, 2 doses alternate timing, 9-valent HPV vaccine, 3 doses standard timing; Biological
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 27 Years to 45 Years · Female only
Enrollment: 618 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Cervical Cancer
Interventions: Cemiplimab, ISA101b; Drug · Biological
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Tucson, Arizona • Orange, California

Conditions: Human Papillomavirus Infections
Interventions: Ad26.HPV16, Ad26.HPV18, MVA.HPV16/18, Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 11
States / cities: Doral, Florida • Fort Myers, Florida • Miami, Florida + 8 more

Conditions: Anal Cancer, HIV Infections
Interventions: Gardasil; Biological
Lead sponsor: Southern California Institute for Research and Education; Other
Eligibility: 18 Years and older · Male only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Human Papilloma Virus-Related Cervical Carcinoma
Interventions: HPV brochure, recall, reminders, General Adolescent Vaccine Brochure; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 11 Years to 18 Years · Female only
Enrollment: 831 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Human Papilloma Virus Infection
Interventions: Tailored education and referral, Staff training and patient reminders, Clinic-level reminder systems; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 9 Years to 70 Years
Enrollment: 53,414 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 2
States / cities: Alhambra, California • San Fernando, California

Search by objective public record fields.

HPV Vaccine Communication ECHO for Primary Care Clinics

Brief Interventions to Increase HPV Vaccine Acceptance in School-based Health Centers

Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males

Quality Improvement Strategies to Increase Human Papillomavirus (HPV) Vaccination

Parent-son-provider Decision-making About HPV Vaccination

Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?

Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women

Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine

Antibody Response to Human Papillomavirus Recombinant Vaccine (Gardasil®) in Girls and Young Women With Chronic Kidney Disease

Perception, Awareness, and Acceptance of Human Papillomavirus Disease and Vaccine Among Parents of Boys Aged 9 to 18 Years

Testing the Use of Prompts to Increase Adolescent Immunization Rates

The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata

Human Papilloma Viruses (HPV) Vaccine Adherence Community Clinic Study

Culturally Tailored HPV Psychoeducational Multimedia Intervention

Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)

Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy

Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

Pilot Study to Determine the Safety and Efficacy of Gardasil Against the Human Papilloma Virus (HPV) in HIV-infected Men

An Intervention Promoting HPV Vaccination in Safety-net Clinics

Increasing Human Papillomavirus Vaccine Uptake in Low-Income, Ethnic Minority Adolescents in Los Angeles County